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Abstract
Mutations in the GJB1 gene, encoding the gap junction (GJ) protein connexin32 (Cx32), cause X-linked Charcot-Marie-
Tooth disease (CMT1X), an inherited demyelinating neuropathy. We developed a gene therapy approach for CMT1X using
an AAV9 vector to deliver the GJB1/Cx32 gene under the myelin protein zero (Mpz) promoter for targeted expression in
Schwann cells. Lumbar intrathecal injection of the AAV9-Mpz.GJB1 resulted in widespread biodistribution in the peripheral
nervous system including lumbar roots, sciatic and femoral nerves, as well as in Cx32 expression in the paranodal non-
compact myelin areas of myelinated fibers. A pre-, as well as post-onset treatment trial in Gjb1-null mice, demonstrated
improved motor performance and sciatic nerve conduction velocities along with improved myelination and reduced
inflammation in peripheral nerve tissues. Blood biomarker levels were also significantly ameliorated in treated mice. This
study provides evidence that a clinically translatable AAV9-mediated gene therapy approach targeting Schwann cells could
potentially treat CMT1X.
Introduction
X-linked Charcot-Marie-Tooth (CMT1X) is the second
most common inherited demyelinating neuropathy [1]
characterized by slowly progressive muscle weakness and
atrophy, loss of reflexes, and reduced nerve conduction
velocities [2–5]. CMT1X affects mostly men with onset at
the age of 5–20 years [5–7], while affected women may
present at a later age [8, 9] with milder symptoms [10].
CMT1X is caused by mutations in the GJB1 gene
encoding the gap junction (GJ) protein connexin 32 (Cx32).
Cx32 is a myelin-related protein that forms intracellular GJ
channels through the non-compact myelin layers at para-
nodal loops and Schmidt–Lantermann incisures of myeli-
nating Schwann cells [11–13] serving important
homeostatic and axon-glial signaling functions. There are
over 400 different GJB1 mutations reported so far
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index.html#/) affecting all domains of Cx32, as well as the
non-coding gene regions [14, 15]. Frameshift, premature
stop, and non-coding mutations are predicted to cause
complete loss of protein function through failed synthesis or
rapid degradation. Several missense and inframe mutations
are retained intracellularly [16–18] in the ER and/or Golgi
[18–22] with the inability to form functional channels,
while other mutants form membrane channels with altered
biophysical characteristics [22].
Despite the large number and different mechanisms of
CMT1X-associated mutations, clinical studies have
demonstrated that males suffering from the disease have a
similar phenotype and severity that correlates with age and
is independent of the specific mutation, comparable with the
phenotype of patients with a complete GJB1 deletion
[23, 24]. Furthermore, Gjb1-null mice with deletion of the
Gjb1/Cx32 gene develop a progressive, predominantly
motor demyelinating peripheral neuropathy beginning at
about three months of age with reduced sciatic motor nerve
conduction velocity (MNCV) and motor amplitude [25, 26].
Expression of wild type (WT) human Cx32 protein driven
by the rat myelin protein zero promoter (Mpz/P0) promoter
prevented demyelination in Gjb1-null mice [27], confirming
that loss of Schwann cell autonomous expression of Cx32 is
sufficient to cause CMT1X pathology. Transgenic mice
expressing CMT1X mutations showed no detectable Cx32
protein in the 175 fs mutant line [28], while R142W, T55I,
R75W and N175D transgenic mice showed retention of the
mutant protein in the perinuclear region and developed a
demyelinating neuropathy similar to Cx32 KO mice
[29, 30]. Taken together, these findings suggest that most
GJB1 mutations cause Schwann cell-autonomous loss of
Cx32 function, indicating that gene replacement therapy is a
valid approach to treat the disease.
We previously showed that a single lumbar intrathecal
injection of a lentiviral vector driven by the Mpz promoter
carrying the GJB1 gene can partially improve the demye-
linating neuropathy in Gjb1-null mice both at early and at
later stages of the disease [31, 32]. However, low levels of
lentiviral derived expression may limit the potential for
translating this approach for a subset of CMT1X patients
with Golgi-retained interfering mutations [33, 34]. In
addition, the mutagenic risk of lentiviral vectors through
genome integration [35] limits their potential to be used in
the treatment of patients. Therefore, we considered as an
alternative approach the use of an adeno-associated viral
vector (AAV). AAV vectors have been extensively used in
the last decades for gene delivery mainly to the central
nervous system (CNS) and in some applications also to the
peripheral nervous system (PNS) [36–39]. Although pre-
vious studies showed that the genes carried by AAV vectors
can be expressed in the PNS, expression was driven by
ubiquitous promoters and was not targeted to Schwann
cells. Thus, the improvement observed could result from
cross-correction through the transfer of the protein from
axons and other cells surrounding the PNS. The Mpz pro-
moter has been used to target Schwannoma cells with
AAV1 vectors resulting in the regression of the tumors
following intraneural injection [40, 41].
In order to develop translatable gene therapy for
CMT1X, we used here an AAV9 vector driven by the
Schwann cell-specific Mpz promoter in order to achieve
targeted GJB1 gene expression in Schwann cells throughout
the PNS. Following a single lumbar intrathecal injection, we
demonstrate widespread vector biodistribution to the lumbar
roots, as well as to sciatic and femoral nerves, leading to
high expression rates of Cx32 specifically in myelinating
Schwann cells. Using this approach, we demonstrate a
significant therapeutic benefit in the CMT1X mouse model
when treated before as well as after the onset of peripheral
neuropathy. This study provides the proof of principle for a
gene therapy approach to treat CMT1X patients.
Materials and methods
Cloning and production of AAV vectors
We generated novel constructs for AAV vector gene
delivery designed to provide Schwann cell-specific
expression of either the reporter gene EGFP (pAAV-Mpz.
Egfp, mock vector; Fig. 1A) or Cx32 (pAAV-Mpz.GJB1,
full, therapeutic vector; Fig. 1B), both under the rat 1.2 kB
Mpz promoter shown to drive expression specifically in
Schwann cells [27, 32]. The Mpz/Cx32 ORF was PCR
amplified from a lentiviral construct previously made in
the lab [42]. The primers used for the amplification were
P0-Cx32-F 5′–AGGGGTACCCTTCCTGTTCAGACT–3′
(SEQ ID No. 13) and P0-Cx32- R 5′–CCGCTCGAGGGA
TCCTC AGCAG–3′. The PCR product (2030 bp) was gel
purified and digested using KpnI and XhoI. The AAV
vector was also digested with the same restriction enzymes.
The entire expression cassette was confirmed by direct
sequencing of the ORFs.
The pAAV-Mpz.Egfp and pAAV-Mpz.GJB1 plasmids
were cross-packaged into AAV9 capsid. For AAV9 vector
production HEK293T, cells are grown in 10 cm tissue
culture dishes in IMDM supplemented with 10% FCS. Two
hours prior to transfection, the medium is changed. When
cells have reached ~70–80% confluency, they are trans-
fected using polyethylenimine (PEI; branched, MW 25,000;
Sigma) with a three-plasmid mix of pAAV, pRepCap, and
pXX6 plasmid provided by Dr. Jude Samulsky, the Uni-
versity of North Carolina at Chapel Hill at a ratio of 1:2:1
and the medium is changed 16 h after transfection. As it was
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shown previously [43] that the cell media contains sig-
nificant amounts of virions, both the cells and the cell
supernatant are collected 48 h later for vector purification.
Cells are pelleted by centrifugation at 500 g for 10 min and
are subsequently re-dissolved in lysis buffer (0.5% sodium
deoxycholate, 150 mM NaCl, 20 mM Tris, 50 U/ml Ben-
zonase; Sigma-Aldrich, Munich, Germany) and incubated at
37 °C for 1 h. The lysate is then clarified by centrifugation
at 3000 g for 10 min and filtered in parallel with the
supernatant through 0.45 µm Millipore filters (Millipore,
San Salvador, El Salvador). Next, RNAseA and a Protease
inhibitor cocktail are added to both the lysate and the
supernatant and incubated for 2 h at 37 °C followed by
clarification at 3000 g for 15 min. The preparations are then
combined with a precipitation mix (PEG/NaCl) at a ratio of
3:1, which is incubated at 4 °C overnight. The mixture is
centrifuged at 3000 g for 30 min and the aqueous super-
natant discarded. The virion-containing pellet is then
resuspended in 3 ml Pellet suspension buffer (250 mM NaCl
solution), which is clarified by centrifugation at 10,000 g for
10 min at 4 °C. The virus-containing aqueous layer is then
transferred to the Beckmann UltraClear SW41 tube and is
centrifuged at 149,000 g for 3 h. The aqueous layer is then
discarded and the viral pellet resuspended in 200 µl pellet
suspension buffer. The vector genome copy number
(VGCN) is determined by qPCR targeting the WPRE
sequence [44].
Experimental animals
In this study, we used adult WT C57BL/6 or Gjb1-null/Cx32
KO (C57BL/6_129) mice weighing 20–25 g. Early and late
gene therapy trials were conducted using 2- and 6-month-old
mice Gjb1-null/Cx32 KO mice weighing 20–25 g. Gjb1-null/
Cx32 KO mice were obtained from the European Mouse
Mutant Archive, originally generated by Prof. Klaus Willecke
(University of Bonn). In these mice, the neor gene was inserted
in-frame into the exon 2 of Gjb1 gene which contains the ORF
[45]. Mice were kept in a specific pathogen-free animal facility,
housed in open-top system cages. Wood bedding for laboratory
mice, dried by high-temperature treatment, sieved, de-dusted,
of high absorbency, was used and mice were housed up to five
in each cage. Standard mouse diet, certificate, for reproduction,
weaning, growth, and tap potable water, filtered and UV ster-
ilized were administered to the mice. Mice were kept in a 12 h
dark/12 h light cycle at a temperature of 22 °C. Both male and
female mice were used in our experiments and showed no (sex-
related) differences in their behavioral performance or nerve
pathology. All experimental procedures in this study were
conducted in accordance with animal care protocols approved
by the Cyprus Government’s Chief Veterinary Officer (project
license CY/EXP/PR.L3/2017) according to national law, which
is harmonized with EU guidelines (EC Directive 86/609/EEC).
Study design
For the analysis of EGFP expression, we used 6 WT mice
injected with the pAAV-Mpz.Egfp (mock) vector and for
Cx32 expression analysis, we used ten Gjb1-null mice
injected with the pAAV-Mpz.GJB1 (full) vector. For the
early treatment study, we used ten Gjb1-null mice injected
with the mock vector and 10 injected with the full vector.
Finally, for the late treatment 20 Gjb1-null mice were used
in the mock group and 20 in the full group. Untreated Gjb1-
null mice (n= 7), as well as WT mice (n= 4) of the same
age, were also assessed for the same outcome measures. We
used 3–4 mice in each group for the expression analysis in
order to obtain reliable data for statistical analysis (t-test).
For the treatment trials, we used 8–12 mice for both elec-
trophysiological and morphological analysis in order to
overcome the variability between mice and obtain reliable
data for statistical analysis. We did not exclude outliers in
case we had. Foot grip tests were performed three times and
the mean value was used while muscle contraction experi-
ments were performed twice.
The aim of this study was to examine whether a gene
addition therapy can treat peripheral neuropathy or prevent
the development of peripheral neuropathy in the mouse
model of CMT1X neuropathy both at early and late stages,
before and after the onset of the neuropathy. The gene
therapy study was conducted using four groups of Gjb1-null
mice. A minimum of 8–12 mice per treatment group for each
outcome measure was considered adequate for assessing
statistically significant differences based on our previous
studies using similar models [32, 42]. Mice were treated at
the age of 2 months for the early treatment and at 6 months
of age for the late treatment (Fig. 2A). Littermate mice were
randomized to receive either AAV9-Mpz.GJB1 (full) treat-
ment or AAV9-Mpz.Egfp (mock treatment, control group)
and were assigned a coding number for further identification.
2-month-old mice were evaluated before the treatment, and
again at the age of 4 and 6 months, while 6-month-old mice
were evaluated before the treatment, and at the age of 8 and
10 months. Mice were evaluated by behavioral testing by an
examiner blinded to the treatment condition and used at the
age of 6 months for the early treatment and 10 months for
the late treatment for electrophysiology or for quantitative
morphometric analysis of semi-thin sections. Animals sub-
jected to muscle contraction experiments were not used for
morphological analysis. Analysis of physiological and
morphological results was also performed blinded to the
treatment condition.
Intrathecal vector delivery
We delivered the AAV vectors by a single lumbar intrathecal
injection as previously described [32, 46]. Briefly, a small
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skin incision was made along the lower lumbar spine level of
anesthetized mice to visualize the spine and the AAV vector
was delivered into the L5-L6 intervertebral space. A 50-μL
Hamilton syringe (Hamilton, Giarmata, Romania) connected
to a 26-gauge needle was used to inject 20 µL of AAV stock
containing an estimated 2 × 1010 vector genomes (vg)/mL, at
a maximum rate of 5 µL/min. A flick of the tail was con-
sidered indicative of successful intrathecal administration.
VGCN determination
Genomic DNA was extracted from different PNS tissues
(i.e., lumbar roots, proximal and distal sciatic nerves, and
femoral motor nerves) of mice 4 or 8 weeks after intrathecal
vector delivery using the Invitrogen iPrep PureLink gDNA
Kit (Thermo Fisher Scientific, Waltham, MA USA). The
extracted DNA was analyzed for yield and purity using a
Nanodrop 1000 spectrophotometer. Approximately 20 ng of
DNA was used as template for two real-time PCR assays on
an Applied Biosystems 7500 Real-Time PCR System
involving 45 cycles of 15 s at 95 °C and 60 s at 60 °C.
TFRC-specific primers/probe targeting the mouse genome
and WPRE-specific primers/probe, which is contained in
the transgene, were used. Standard curves were created by
serial dilution of quantified mouse genomic DNA, as well
as quantified plasmid DNA containing the transgene cas-
sette. The average VCN per cell was calculated as the total
VCN divided by the total cell number.
Immunofluorescence staining
For immunostaining, mice were anesthetized with avertin
according to institutionally approved protocols, and then
transcardially perfused with normal saline followed by fresh
4% paraformaldehyde in 0.1M PB buffer. The lumbar-sacral
spinal cords with spinal roots attached, as well as the bilateral
sciatic and femoral motor nerves were dissected and post-fixed
in 4% PFA, the spinal cord for 2 h while sciatic and femoral
nerves for 30min. Spinal roots were frozen for cryosections
while sciatic and femoral nerves were isolated and teased into
fibers under a stereoscope. Teased fibers or sections were
permeabilized in cold acetone and incubated at RT with a
blocking solution of 5% BSA (Sigma-Aldrich, Munich, Ger-
many) containing 0.5% Triton-X (Sigma-Aldrich, Munich,
Germany) for 1 h. Primary antibodies used were: mouse
monoclonal antibody against the contactin-associated protein
(Caspr, 1:50; gift of Dr. Elior Peles, Weizmann Institute of
Science), NeuN (1:400 Chemicon, San Salvador, El Salvador),
CC1 (1:50, Calbiochem, San Salvador, El Salvador), GFAP
(1:400, Sigma-Aldrich, Munich, Germany), rabbit antisera
against EGFP (1:1,000; Invitrogen, Waltham, MA USA),
Caspr2 (1:200, Alomone Labs, Jerusalem, Israel), CD3 (1:100;
Abcam, Cambridge, UK) and Cx32 (1:50; Invitrogen,
Waltham, MA USA), rat CD68 (1:50; Biorad, California,
USA), CD45 (1:100; Abcam, Cambridge, UK) and goat CD20
(1:100; Santa Cruz, Texas, USA) all diluted in blocking solu-
tion and incubated overnight at 4 °C. Slides were then washed
in PBS and incubated with mouse cross-affinity fluorescein-
conjugated (1:1000; Invitrogen, Waltham, MA USA), rat
cross-affinity purified rhodamine-conjugated (1:2000; Invitro-
gen, Waltham, MA USA), goat cross-affinity fluorescein-con-
jugated (1:700; Abcam, Cambridge, UK) and rabbit cross-
affinity purified rhodamine-conjugated (1:500; Jackson
ImmunoResearch, West Grove, USA) secondary antibodies for
1 h at RT. Cell nuclei were visualized with DAPI (1 µg/ml;
Sigma, Munich, Germany). Slides were mounted with fluor-
escent mounting medium and images photographed under a
fluorescence microscope with a digital camera using a fluor-
escence microscope (Nikon Eclipse Nἱ; Tokyo, Japan) with a
digital camera (DS-Qi2) using NIS-Elements software.
Immunoblot analysis
Fresh sciatic and femoral nerves and lumbar spinal roots
were collected at 8 weeks post-injection and lysed in ice-
cold RIPA buffer (10 mM sodium phosphate, pH 7.0, 150
mM NaCl, 2 mM EDTA, 50 mM sodium fluoride, 1%
Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS all
from Sigma-Aldrich, Munich, Germany) containing a
mixture of protease inhibitors (Roche, Sigma-Aldrich,
Munich, Germany). Proteins (150 μg) from the lysates were
fractionated by 12% SDS/PAGE and then transferred to a
Hybond-C Extra membrane (GE Healthcare Life Sciences,
Logan, USA) using a semidry transfer unit. Nonspecific
sites on the membrane were blocked with 5% non-fat milk
in PBS with Tween 20 (PBST) for 1 h at room temperature.
Immunoblots were incubated with rabbit antisera against
EGFP (1:1000; Abcam, Cambridge, UK) or Cx32 (clone
918, 1:3000) [47] and mouse β-tubulin (1:4000; Develop-
mental Studies Hybridoma Bank, Iowa, USA) at 4 °C
overnight. After washing, the immunoblots were incubated
with an anti-mouse or anti-rabbit HRP-conjugated second-
ary antiserum (Jackson ImmunoResearch, diluted 1:3000,
West Grove, USA) in 5% milk–PBST for 1 h. The bound
antibody was visualized by an enhanced chemilumines-
cence system (GE Healthcare Life Sciences, Logan, USA).
Behavioral analysis
Grip strength testing
To measure grip strength, mice were held by the tail and
lowered towards the apparatus (Ugo Basile, Varese, Italy) until
they grabbed the grid with the hind paws. Mice were gently
pulled back until they released the grid. Measurements of the
force in g were indicated on the equipment. Each session
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consisted of three consecutive trials and measurements were
averaged. Hind limb force was compared between AAV9.Mpz-
GJB1 and AAV9.Mpz-Egfp treated mice.
Electrophysiological analysis
Motor nerve conduction velocity (MNCV)
MNCV was measured in vivo using published methods [48]
from bilateral sciatic nerves following stimulation in anes-
thetized animals using two stimulation sites, one near the
sciatic notch and one distally at the ankle via bipolar elec-
trodes with supramaximal square-wave pulses (5 V) of
0.05 ms. The latencies of the compound muscle action
potentials (CMAP) were recorded by a bipolar electrode
inserted between digits 2 and 3 of the hind paw and mea-
sured from the stimulus artifact to the onset of the negative
M-wave deflection. MNCV was calculated by dividing the
distance between the stimulating and recording electrodes
by the result of subtracting distal from proximal latency.
Quadriceps muscle contractility study
Quadriceps muscle contractility study was performed only in
the late treatment group in order to assess in situ the function
of the lumbar root and femoral motor axons. Mice subjected to
muscle contraction study were not used for morphological
assessment. We measured the contraction properties of the
quadriceps muscle innervated by the femoral nerve in an
anesthetized mouse as previously described [32]. After expo-
sure of the motor part of the femoral nerve a stimulating hook
electrode was used to stimulate the motor branch of the
femoral nerve at 1 Hz using a constant current stimulator
(DS3; Digitimer, Welwyn Garden City, UK) with 5–6mA and
200 μs duration pulse. The muscle contraction of the partially
exposed quadriceps muscle was recorded with a force dis-
placement transducer (FT03; Grass Technologies), which was
attached to the muscle with a silk suture. The transducer was
connected to a micromanipulator and for the experiment the
muscle was extended 1mm each time until the muscle con-
traction reached the maximum value. The average amplitude
and duration of the force generated by the quadriceps muscle
contraction was compared between treatment groups.
Biomarkers determination in blood samples of
Gjb1-null treated mice
In order to further access the potential value of clinically
relevant blood biomarkers and their treatment responsive-
ness, we performed biomarker analysis from blood samples
of WT compared to untreated Gjb1-null mice, as well as
from Gjb1-null mice treated either with the therapeutic or
with the mock vector, all at the age of 10 months. Blood
was collected prior to sacrificing the animals using standard
methods [49]. We measured the levels of neurofilament
light (NF-L) and neural cell adhesion molecule (NCAM-1).
Measurement of NF-L concentration
Blood samples were processed within one hour. Blood was
collected into EDTA-containing tubes and centrifuged at 20 °C
at 3500 rpm for 10min. Plasma was aliquoted and stored at
−80 °C until testing. Plasma NF-L concentration was mea-
sured at University College London (UCL) using a commer-
cially available NF-Light kit on a Single molecule array
(Simoa) HD-1 instrument (Quanterix, Billerica, MA) [50, 51].
Measurement of NCAM-1 concentration by ELISA
Serum was separated using 0.5 ml Minicollect Z serum
separation tubes. Blood samples were taken and centrifuged
20 °C at 3000 g for 10 min. Serum was aliquoted and stored
at −80 °C until testing. Serum protein levels were deter-
mined at the Department of Clinical Neurosciences, Uni-
versity of Cambridge, by ELISA according to
manufacturers’ instructions for neural cellular adhesion
molecule (NCAM1; Rockland KOA0716).
Morphometric analysis of myelination in lumbar
roots and peripheral nerves
Mice were transcardially perfused with 2.5% glutar-
aldehyde in 0.1 M PB buffer. The lumbar spinal cord
with multiple spinal roots attached, as well as the
femoral and sciatic nerves, were dissected and fixed
overnight at 4 °C, then osmicated, dehydrated, and
embedded in araldite resin (all purchased from Agar
Scientific, Essex, UK). Transverse semi-thin sections
(1 μm) of the lumbar spinal cord with roots and the
middle portion of the femoral motor and sciatic nerves
were obtained and stained with alkaline toluidine blue
(Sigma-Aldrich, Munich, Germany). Sections were
visualized with 10×, 20×, and 40× objective lenses and
captured using a Nikon Eclipse Ni microscope (Tokyo,
Japan) with a digital camera (DS-Fi3) using NIS-
Elements software. Images of whole root or transverse
nerve sections were obtained at 100–200× final magni-
fication, and a series of partially overlapping fields
covering the entire cross-sectional area of the roots or the
nerves were captured at 400× final magnification.
These images were used to examine the degree of
abnormal myelination in all treatment groups as described
previously [30, 42, 52]. In brief, all demyelinated, remye-
linated, and normally myelinated axons were counted in the
entire root or nerve cross-section using the following cri-
teria: axons larger than 1 μm without a myelin sheath were
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considered demyelinated; axons with myelin sheaths <10%
of the axonal diameter and/or axons surrounded by “onion
bulbs” (i.e., circumferentially arranged Schwann cell pro-
cesses and extracellular matrix) were considered remyeli-
nated; all other myelinated axons were considered normally
myelinated.
In addition, we counted the number of foamy macro-
phages present within the entire cross section of each root
or nerve, as an indication of inflammation. Macrophages
were identified in semi-thin sections at 400× magnifica-
tion as cells laden with myelin debris, devoid of a base-
ment membrane, and extending small, microvilli-like
processes, as described previously [53, 54]. The macro-
phage count was calculated as the ratio per 1000 myeli-
nated fibers, to account for size differences between
different spinal roots and nerves. All pathological ana-
lyses were performed blinded to the treatment condition
of each mouse.
Statistical analysis
The percentages of EGFP-positive Schwann cells or Cx32-
expressing paranodal myelin areas in immunostained spinal
roots and sciatic nerves of WT and Gjb1-null mice injected
with the mock or full vector, respectively, were compared
with Student’s t-test. Behavioral testing results, electro-
physiological results, and blood biomarker levels were
compared using one-way ANOVA with Bonferroni post-
test. Morphological analysis data obtained from mock-
treated and fully treated groups were compared using the
Mann–Whitney U test (significance level for all compar-
isons, P < 0.05). All tests were performed using GraphPad
Instat3 software (GraphPad, San Diego, USA).
Results
EGFP expression following intrathecal injection of
AAV9-Mpz.Egfp
AAV9 vectors (both mock and full) were produced to titers of
1 × 1012 vg/ml. AAV9-Mpz.Egfp (mock vector; Fig. 1A) was
delivered by lumbar intrathecal injection (estimated 2 × 1010 vg
injected) into WT mice in order to study the biodistribution of
the vector throughout the PNS. VGCNs and EGFP expression
were examined 8-weeks post-injection in anterior lumbar roots
and sciatic nerves. EGFP was detected by immunofluorescent
labeling (Fig. 1C, E) as well as by auto-fluorescence without
the use of an antibody (Fig. 1D) in the perinuclear cytoplasm of
a subset of Schwann cells in both the lumbar roots and sciatic
nerves. VGCNs in DNA extracted from PNS tissues reached
0.24 ± 0.09 in anterior lumbar roots, 0.82 ± 0.46 in the prox-
imal part of the sciatic nerve and 0.18 ± 0.08 in the distal part
of the sciatic nerve (n= 4 mice; Fig. 1F). EGFP expression
rates in immunostained tissue sections reached 35.0 ± 3.23 %
in anterior lumbar roots and 39.9 ± 2.49 % in sciatic nerves (n
= 3 mice; Fig. 1G). EGFP was also detected by immunoblot
analysis of lumbar roots, sciatic and femoral nerve samples of
injected mice with a proximal to distal expression level gra-
dient, while it was not detected in non-injected WT mouse
samples run as negative controls (Fig. S1A–C).
In order to confirm the cell-specificity of the Mpz pro-
moter we performed double immunostaining for EGFP
with cell markers in lumbar spinal cord sections and
confirmed that EGFP expression was not detected in oli-
godendrocytes, neurons, or astrocytes (Fig. S2A–C).
Likewise, staining of sciatic nerve sections with vimentin,
a fibroblast marker, and Glut-1, a perineurial cell marker,
showed no EGFP expression either in fibroblasts or in
perineurial cells (Fig. S2D, E). Furthermore, in order to
exclude an inflammatory response that could occur after
intrathecal injection of the vector we immunostained sec-
tions of spinal cord with anterior lumbar roots attached
using different inflammatory cell markers. We did not
detect any CD68+ macrophages, CD3+ T lymphocytes,
CD45+ leukocytes or CD20+ B-lymphocytes in CNS or
PNS tissues of injected mice (Fig. S3).
Cx32 expression following intrathecal injection of
AAV9-Mpz.GJB1
AAV9-Mpz.GJB1 (full, therapeutic vector; Fig. 1B) driving
expression of the human GJB1 open reading frame was
delivered by lumbar intrathecal injection (estimated 2 × 1010 vg
injected) into both 2- and 6-month-old Gjb1-null mice in order
to study the expression of Cx32 throughout the PNS in the
absence of endogenous Cx32 at the age groups relevant for the
treatment trials. Cx32 expression and VGCNs were determined
4 weeks post-injection in anterior lumbar roots and sciatic
nerves. Cx32 was detected as expected at the paranodal areas
of myelinating Schwann cells in both lumbar roots and sciatic
nerves, similar to the WT tissues (Fig. 1H–M). At 4 weeks
post-injection, VGCNs reached 0.2 ± 0.05 (n= 4 mice) in
anterior lumbar roots and 0.18 ± 0.07 in the sciatic nerve (n= 4
mice; Fig. 1N). We also measured the VGCNs in other tissues
including the quadriceps muscles (0.05 ± 0.03), the spinal cord
(0.17 ± 0.08), and the liver (17.32 ± 3.30). The percentage of
Cx32-immunoreactive paranodal areas among all paranodal
areas visualized in each tissue based on Caspr paranodal
labeling was quantified reaching 62.7 ± 3.75 % in anterior
lumbar roots (n= 5 mice) and 69.9 ± 6.90 % in sciatic nerves
(n= 5 mice) (Fig. 1O). Immunoblot analysis confirmed high
expression levels of Cx32 in anterior lumbar root and sciatic
nerve lysates from injected animals similar to animals trans-
genically expressing Cx32, while Cx32 was absent in non-
injected Gjb1-null mice tissues (Fig. S1D, C).
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Fig. 1 Biodistribution and expression of AAV9-Mpz.Egfp and
AAV9-Mpz.GJB1 vectors. Diagrams showing the expression cas-
sette of the AAV9-Mpz.Egfp (mock) (A) and AAV9-Mpz.GJB1
(full) (B) vectors, in which the expression of either the EGFP
reporter gene or of the human GJB1 open reading frame, respec-
tively, is driven by the rat myelin protein zero (Mpz) promoter.
Immunostaining for EGFP (red) of lumbar root sections (C) and
sciatic nerve teased fibers (E) reveals perinuclear EGFP immunor-
eactivity (arrows) in a subset of Schwann cells 8 weeks after intra-
thecal injection of AAV9-Mpz.Egfp vector in wild type (WT) mice.
Auto-fluorescent EGFP signal (green) is also evident in sciatic nerve
sections without antibody detection (D). Cell nuclei are stained with
DAPI (blue). Determination of the vector genome copy numbers
(VGCN) confirms AAV9 biodistribution to lumbar roots (LR) as
well as both proximal (prox) and distal (dis) sciatic nerves (SN) (F).
Quantification of the percentage of EGFP-positive cells in lumbar
roots and sciatic nerves shows no significant differences between
PNS tissues examined at 8 weeks post-injection (G). Following
injection of AAV9-Mpz.GJB1 in Gjb1-null mice immunostaining of
lumbar root sections (H)–(J) and sciatic nerve teased fibers (K)–(M)
for Cx32 (red) and paranodal axonal marker Caspr (white arrows)
shows that virally delivered Cx32 (red arrows) is correctly expressed
at some of the paranodal myelin areas (white arrows) only in
injected Gjb1-null mice (J) and (M) similar to WT mice (H) and (K)
but not in their non-injected Gjb1-null littermates (I) and (L). Cx32
is also detected in the Schmidt-Lanterman incisures (yellow arrows)
in both WT (A) and AAV9-Mpz.GJB1 injected mice (J) and (M).
N VGCN determination demonstrates biodistribution of AAV9-Mpz.
GJB1 to both lumbar roots and sciatic nerves in addition to the
spinal cord (SC) and to a lesser degree to the quadriceps muscle.
O Quantification of the percentage of Cx32-positive paranodal areas
in lumbar roots and sciatic nerves shows comparable results in both
tissues. VGCNs and expression rates values represent Mean ± SEM.
Scale bars: (C) and (D): 20 μm; (E)–(M): 10 μm.
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Fig. 2 Analysis of functional outcomes of AAV9-Mpz.GJB1 injec-
ted Gjb1-null mice compared to AAV9-Mpz.Egfp (mock) treated
littermates. A Diagram showing the pre- and post-onset treatment
trial time course with a timing of functional and morphological
analysis. Results of foot grip analysis in pre- (B)–(E) and post-onset
treatment groups (F)–(I) comparing AAV9-Mpz.GJB1 treated
(GJB1) and mock-treated Gjb1-null mice, as indicated. There were
no differences between the treatment groups before the injection (B)
and (F), while 2 months post-injection grip strength improved in
both pre- and post-onset treated Gjb1-null mice compared to the
mock groups (n= 10 per group) (C) and (G). The improved per-
formance continued at 4 months post-injection in both pre- (6-
month old) and post-onset (10-months old) treated mice compared
to controls and was not significantly different from the performance
of wild type (WT) mice of the same age (D) and (H). Longitudinal
analysis within each group showed improved motor performance
over time in both pre- and post-onset treated Gjb1-null mice while
mock groups did not improve (E) and (I). Sciatic nerve motor
conduction velocity (MNCV) also showed significant improvement
4 months after treatment compared to the mock groups in both pre-
(J) and post-onset (K) treated mice (n= 10 for all groups). MNCVs
in early treated mice did not differ significantly from those of age-
matched WT mice (J) while in post-onset treated mice they
remained below those of age-matched WT mice (K) (One-
way ANOVA with Bonferroni post-test; *P < 0.05, **P < 0.01 and
***P < 0.001).
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Improvement of motor performance in pre- and
post-onset treated Gjb1-null mice
Following confirmation of therapeutic vector expression in
both 2- and 6-month-old Gjb1-null mice, we proceeded
with pre- and post-onset treatment trials in which littermate
mice were randomized into two groups, one receiving the
mock (AAV9-Mpz.Egfp) and the other the full (AAV9-Mpz.
GJB1) vector. Pre-onset treatment groups were injected at
2 months of age and monitored until 6 months of age when
outcome was assessed by behavioral, electrophysiological
and morphological analysis. Post-onset treatment groups
were injected at 6 months of age and outcome was similarly
assessed at 10 months of age, with additional biomarker
analysis (Fig. 2A).
Motor performance was assessed before the injection and
until the end of the observation period by foot grip analysis
in all groups (Fig. 2B–E). Foot grip strength in pre-onset
groups at the age of 2 months, at baseline before the
initiation of the treatment, showed as expected no difference
between the two groups or the WT (p > 0.05) with values
reaching 66.6 ± 3.59 g for the full vector group (n= 10),
71.0 ± 6.69 g for the mock vector group (n= 10) and 76.6 ±
5.87 g for the WT group (n= 12). At the age of 4 months,
2 months post-injection, muscle strength was increased in
fully treated mice reaching 74.3 ± 3.57 g (n= 10) compared
to the mock group (53.4 ± 5.0; n= 10; p > 0.05) but without
reaching the WT values (116.0 ± 8.06 g; n= 12; p <
0.0001). At 4 months post-injection the force generated by
the hindlimbs of the treated mice was increased reaching
120.0 ± 7.87 g (n= 10) compared to the mock group (69.3
± 3.59 g; n= 10; p < 0.001) and was similar to the WT
values (106.6 ± 2.89; n= 12; p > 0.05). Longitudinal com-
parison at different age groups of fully treated mice showed
that the force generated by the hindlimbs increased sig-
nificantly over time (p < 0.0001), while mock treated mice
did not show any differences (p > 0.05).
Foot grip analysis in post-onset treatment groups
(Fig. 2F, I) showed no differences at baseline with the
values of the fully treated group reaching 74.5 ± 5.46 g (n=
21) and the mock 76.0 ± 9.14 g (n= 20), while both per-
formed worse than WT mice of the same age (106.6 ± 2.89;
n= 12; p < 0.01). At the age of 8 months, 2 months post-
injection, we observed an increase in the force generated by
the hindlimbs in the fully treated compared to the mock
groups reaching 93.5 ± 5.18 g (n= 21) and 76.2 ± 3.41 g
(n= 20; p < 0.05), respectively with the fully treated group
reaching values similar to those of the WT mice (103.8 ±
5.26; n= 12; p > 0.05). At the final stage, at 10 months of
age, we observed further improvement of the force in fully
treated mice (103.4 ± 6.01 g; n= 21), compared to the mock
group (73.2 ± 5.15 g; n= 20; p < 0.01) with no significant
difference to WT values (109.6 ± 7.46 g; n= 16; p > 0.05).
Longitudinal comparison of the motor performance at dif-
ferent time points within each treatment group showed that
fully treated mice improved significantly 2 months post-
injection, from 6 to 8 months of age (p= 0.0441) and even
further from 8 to 10 months of age (p= 0.0045), while
mock-treated littermates did not show any significant dif-
ferences over time (p > 0.05). Overall, our motor perfor-
mance findings at different stages of the treatment trials
indicate a continuous improvement of motor performance in
both pre- and post-onset treatment groups following the
delivery of the AAV9-Mpz.GJB1 vector.
Improvement of electrophysiological properties of
pre- and post-onset AAV9-Mpz.GJB1 treated
Gjb1-null mice
In the pre-onset treatment groups, we performed sciatic
MNCV studies at the age of 6 months, 4 months after vector
injection. MNCV was improved in the fully treated mice
compared to the mock group (n= 10 mice per group) as
indicated by the values that reached 37.5 ± 1.81 m/s in the
fully treated group and 28.3 ± 1.92 m/s in the mock group
(p < 0.01) (Fig. 2J) without significant difference to the WT
values at the same age (41.7 ± 1.09; n= 11; p > 0.05).
Although MNCV was improved in the fully treated mice the
amplitude of the CMAP was similar between the two
groups reaching 4.6 ± 0.56 mV (n= 10) in the mock group
and 4.1 ± 0.49 mV (n= 10) in the full group (p > 0.05;
Fig. S4A).
In the post-onset treated groups, we performed both
MNCV and quadriceps muscle contraction experiments that
reflect chronic axonal loss and muscle denervation. Mea-
surements were performed at 10 months of age, 4 months
post-injection. MNCV was improved in the fully treated
mice (34.8 ± 1.44 m/s; n= 11) compared to the mock group
(30.4 ± 0.87 m/s; n= 10) (p < 0.05; Fig. 2K) but remained
significantly below the values of age-matched WT mice
(43.7 ± 1.05; n= 11; p < 0.001). As in the early treated
groups, we also measured the CMAP amplitudes and found
no significant differences between the two groups (p > 0.05)
with the values reaching 4.1 ± 0.42 mV (n= 11; full group)
and 3.2 ± 0.35 mV (n= 10; mock group; Fig. S4B). We
further examined the muscle contractility properties of the
quadriceps muscle after stimulation of the femoral motor
nerve in situ (Fig. S4C, D) as previously described [32].
Both force and duration were improved in the AAV9-Mpz.
GJB1 treated (n= 11) compared to the mock-treated (n=
10) group. Amplitudes reached 0.22 ± 0.010 N in the treated
group, similar to WT [32], and 0.18 ± 0.008 N in the mock
group (p= 0.0059). Furthermore, the duration of contrac-
tion was significantly increased in the treated group reach-
ing 0.098 ± 0.004 sec compared to 0.084 ± 0.002 s in the
mock group (p= 0.0015). Overall, our electrophysiological
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studies with emphasis on motor fibers that are pre-
dominantly affected in this CMT1X model [26, 30] showed
significant improvement following both pre- as well as post-
onset gene addition therapy.
Establishment of treatment-responsive blood
biomarkers in the CMT1X model
Based on previous data showing that biomarkers can be used
in order to access treatment outcome in CMT neuropathy
models [31, 74] we performed further analysis of blood
samples for disease-relevant biomarkers including Neurofi-
lament light (NF-L) and neuronal cell adhesion molecule-1
(NCAM-1). Clinical studies have shown elevation of plasma
NF-L levels in patients with different CMT types including
CMT1X compared to controls, as well as a correlation
between elevated concentrations and disease severity, sug-
gesting that this may be a useful biomarker for assessing
disease progression and potential response to treatment in
future clinical trials [51]. In keeping with our previous
observations [31], we found that plasma NF-L levels were
increased in untreated 10-month old Gjb1-null mice (246.84
± 20.18 pg/ml) compared to age-matched WT mice (111.48
± 26.77 pg/ml; p < 0.001). Moreover, comparison of treat-
ment groups (n= 6 mice per group) showed that NF-L
levels were significantly ameliorated in Gjb1-null mice
treated post-onset at the age of 6 months (152.4 ± 9.7 pg/ml;
range: 124.9–191.2) compared to mock vector treated lit-
termates (245.5 ± 13.4 pg/ml; range: 197.3–280.7; Fig. 3A;
p < 0.05). This reduction of NF-L levels in the AAV9-Mpz.
GJB1 treatment group by 1.6-fold compared to the mock
group is in accordance with their improved motor function
indicating that NF-L levels can be used as a treatment-
responsive and clinically relevant biomarker for future gene
therapy.
In addition to NF-L, we evaluated NCAM-1, a novel
blood biomarker with potential relevance to peripheral nerve
disease. Similar to NF-L, analysis of NCAM-1 levels showed
an elevation in untreated Gjb1-null mice (179787.4 ± 6953.2
nmol/μl; n= 4) compared to WT mice (135494.5 ± 10649.9
nmol/μl; n= 3; p > 0.05; Fig. 3B). Importantly, there was
a significant amelioration of NCAM-1 elevation in the
treated group (140651.6 ± 6798.4 nmol/μl; n= 7) compared
to the mock-treated mice (196598 ± 9424.6 nmol/μl; n= 7;
p < 0.001).
Improved pathology in pre-onset AAV9-Mpz.GJB1
treated Gjb1-null mice
We performed a morphological analysis in transverse
semithin sections of anterior lumbar roots, mid-sciatic and
femoral motor nerves of 6-month-old Gjb1-null mice
injected at the age of 2 months with either the full (AAV9.
Mpz-GJB1) or the mock (AAV9.Mpz-Egfp) vector. Multiple
roots, bilateral sciatic and femoral motor nerves from each
mouse were examined and the ratio of abnormally myeli-
nated fibers was counted and their proportion to the total
number of fibers was calculated [32, 33, 42]. We also
counted the number of foamy macrophages in each section
[32], and calculated their numbers per 1,000 myelinated
fibers (to account for variations in root and nerve size). In
the anterior lumbar roots, a reduction of the abnormally
myelinated fibers and foamy macrophages was observed in
early AAV9-Mpz.GJB1 treated mice compared to their
mock-treated littermates (Fig. 4A–D). The ratio of abnor-
mally myelinated fibers reached 0.12 ± 0.02 in the fully
treated group compared to 0.18 ± 0.02 in the mock-treated
mice (n= 10 mice per group; p= 0.0232; Fig. 4E and
Table S1). Reduction was also observed in the number of
foamy macrophages that reached 5.2 ± 0.97/1000 fibers in
Fig. 3 Improvement of blood biomarkers after treatment in Gjb1-
null mice. Analysis of blood levels of molecules relevant to nerve
pathology in 10-month-old AAV9-Mpz.GJB1 treated (GJB1) Gjb1-
null mice compared to AAV9-Mpz.Egfp (mock) treated littermates, as
well as age-matched WT and untreated Gjb1-null mice: A Neurofila-
ment light (NF-L) plasma concentration is increased in Gjb1-null (n=
5) compared to WT (n= 8) mice and shows significant amelioration in
post-onset treated mice compared to mock treated mice (n= 6 per
group). B: Neural cell adhesion molecule-1 (NCAM-1) serum levels
were similarly increased in untreated Gjb1-null (n= 4) compared to
WT (n= 3) mice and showed significant improvement in treated
compared to mock-treated group (n= 7 per group) (one-way ANOVA
with Bonferroni post-test; *P < 0.05, **P < 0.01 and ***P < 0.001).
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the treated group and 12.7 ± 1.60 in the mock group (p=
0.0009; Fig. 4F and Table S1).
Likewise, in femoral motor nerves, the ratio of abnormally
myelinated fibers and the numbers of foamy macrophages
were reduced after gene therapy (Fig. 4G–J). The ratio of
abnormally myelinated fibers was 0.20 ± 0.01 in the treated
group and 0.38 ± 0.02 in the mock group (n= 10 per group;
p < 0.0001; Fig. 4K and Table S3), while foamy macrophages
were reduced to 6.1 ± 0.30/1000 fibers in the treated group
compared to 13.4 ± 0.54 in the mock group (p < 0.0001;
Fig. 4L and Table S3). The sciatic nerves showed similar
results (Supplementary results, Table S2 and Fig. S5A–F).
Fig. 4 Morphological analysis of anterior lumbar roots and
femoral motor nerves of Gjb1-null mice following pre-onset
intrathecal delivery of the AAV9-Mpz.GJB1 vector. These are
representative images of semithin sections of anterior lumbar spinal
roots attached to the spinal cord at low (A) and (B) and higher (C) and
(D) magnification, with morphometric analysis results (E) and (F), as
well as of semithin sections of femoral motor nerves at low (G) and
(H) and higher (I) and (J) magnification and corresponding morpho-
metric analysis results (K) and (L), from mock and full vector treated
mice as indicated, at 6 months of age (4 months after treatment).
AAV9-Mpz.GJB1 injected mice show improved myelination in all
tissues compared to mock-treated littermates with fewer demyelinated
(*) and remyelinated (r) fibers. Quantification of the ratios of abnor-
mally myelinated fibers in multiple roots and femoral nerves (n= 10
mice per group) confirms significant improvement in the numbers of
abnormally myelinated fibers (E) and (K), as well as reduction in the
numbers of foamy macrophages (F) and (L) in the treated compared
with mock treated littermates (see also Tables S1 and S3). Scale bars:
(A, B), (G, H) 50 μm, (C, D), (I, J) 10 μm.
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Improved pathology in post-onset AAV9-Mpz.GJB1-
treated Gjb1-null mice
As with early, pre-onset treatment groups, we performed a
morphological analysis in transverse semithin sections of
anterior lumbar roots, mid-sciatic, and femoral motor nerves
of 10-month-old Gjb1-null mice injected either with the full
or mock vector at the age of 6 months. Tissues of 10-month
old WT and untreated Gjb1-null mice were also examined
for assessment of the magnitude of the therapeutic effect. In
anterior lumbar roots, similar to the early treated mice, post-
onset treated mice showed improvement in morphological
properties with a reduced ratio of abnormally myelinated
fibers and numbers of foamy macrophages (Fig. 5A–D).
The ratio of abnormally myelinated fibers decreased to 0.22
± 0.03 in the treatment group (n= 10) compared to 0.32 ±
0.02 in the mock group (n= 10; p= 0.0147) (Fig. 5E and
Table S4). Furthermore, the number of foamy macrophages
was 9.31 ± 1.2/1000 fibers in the full group (n= 10) com-
pared to 14.85 ± 1.38 in the mock group (n= 10; p=
0.0068) (Fig. 5F and Table S4). The sciatic nerves showed
similar results (Supplementary results, Table S5 and
Fig. S5G–L).
Finally, as in lumbar motor roots and sciatic nerves, we
observed improved morphological properties also in the
femoral motor nerves of post-onset treated mice
(Fig. 5G–J), where the ratio of abnormal fibers reached
0.21 ± 0.009 in the treated group compared to 0.33 ± 0.012
in the mock group (n= 10 per group; p < 0.0001) (Fig. 5K
and Table S6). Moreover, foamy macrophages were
reduced to 4.9 ± 0.73/1000 fibers in the treated group (n=
10) compared to 10.0 ± 0.47 in the mock group (n= 10; p <
0.0001) (Fig. 5L and Table S6). Thus, our morphological
analysis of the PNS tissues revealed a significant
improvement of the pathology including de- and remyeli-
nation and inflammatory changes that are characteristic of
this model of CMT1X both in pre- as well as in post-onset
treated mice. However, morphological improvement in
treated mice was only partial, as demonstrated by the
comparison to WT tissues (Tables S4–S6). On the other
hand, comparison of 10-month old mock treated with
untreated Gjb1-null mice of the same age showed similar
degree of pathology (Supplementary results, Fig. S6, and
Tables S4–6), indicating that mock vector injection and
EGFP expression had no detrimental effects in this model.
Discussion
In this study, we used an AAV9 vector for targeted gene
delivery to Schwann cells in order to treat the peripheral
neuropathy in the Gjb1-null mouse model of CMT1X.
Using the GJB1 gene coding sequence driven by the rat
Mpz promoter with known specificity for myelinating
Schwann cells [27, 32] we delivered by a single lumbar
intrathecal injection the AAV9 vector into 2- and 6-month-
old Gjb1-null mice and achieved widespread expression of
the virally delivered human Cx32. This treatment resulted in
significant improvements in all outcome measures in this
neuropathy model both when treated at early as well as at
later stages of the disease.
AAV vectors are known to provide high expression
levels in transduced cells [55–57] offering the potential to
treat patients with different CMT1X mutations, including
those with potential dominant-negative effects [33]. More-
over, the use of AAV vector provides a more translatable
approach since these vectors remain mostly episomal
minimizing the risk for insertional mutagenesis [58]. In
contrast, lentiviral vectors integrate into the host genome
[35] increasing the risk for mutagenesis and therefore have
limited potential for systemic in vivo delivery. Importantly,
the AAV9 vector is already used in clinical trials with an
established safety profile and recently FDA-approved
application for the treatment of spinal muscular atrophy.
Intrathecal injection of the AAV9 vector resulted in
widespread expression of the reporter gene EGFP in WT
mice as well as of Cx32 in both 2- and 6-month-old Gjb1-
null mice. Analysis of vector genomes in PNS tissues
indicates a gradient of biodistribution from proximal to
distal PNS tissues, although there was considerable varia-
bility between animals. As expected, muscle and spinal cord
transduction by the AAV vectors were also evident, but
EGFP or Cx32 expression was restricted to myelinating
Schwann cells under the control of Mpz promoter. More-
over, we demonstrate that virally delivered Cx32 is cor-
rectly localized in the paranodal areas of myelinating
Schwann cells as previously achieved with lentiviral gene
delivery [31, 32]. However, AAV9 appears to provide
higher expression rates and levels as evident by the
immunoblot analysis in PNS tissues of injected mice. In this
study, we injected AAV amounts of 2 × 1010 vg. Higher
vector titers allowing the injection of more viral particles
exceeding >1011 vg may improve further the biodistribution
into the PNS and expression rates. Furthermore, it remains
to be shown whether the biodistribution achieved by intra-
thecal injection can be also obtained in a larger animal to
support the clinical application.
Although AAV9 provided higher Cx32 expression levels
compared to our previous studies, only a subset of Schwann
cells expressed the gene of interest resulting only in partial
phenotype correction. Interestingly, it appears that restoring
Cx32 function in at least 50% of myelinating Schwann cells
in PNS tissues may be sufficient to provide significant
functional and morphological improvement in this model
and potentially also in CMT1X patients. This partial cor-
rection may reflect the situation caused by the random X
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chromosome inactivation in female patients affected by
CMT1X, who typically present with a milder and non-
progressive phenotype [59]. As thousands of myelinating
Schwann cells are needed to myelinate the length of a single
axon, there may be a threshold of functioning Schwann
cells ratio for maintaining axon survival explaining why the
correction of a subset of Schwann cells was sufficient to
improve the outcome in the disease model.
Fig. 5 Morphological analysis of anterior lumbar roots and
femoral motor nerves of Gjb1-null mice following post-onset
intrathecal delivery of the AAV9-Mpz.GJB1 vector. These are
representative images of semithin sections of anterior lumbar spinal
roots attached to the spinal cord at low (A) and (B) and higher (C) and
(D) magnification, with morphometric analysis results (E) and (F), as
well as of semithin sections of femoral motor nerves at low (G) and
(H) and higher (I) and (J) magnification with related morphometric
analysis results (K) and (L), from mock and full (GJB1) vector treated
mice as indicated, at 10 months of age (4 months after treatment).
AAV9-Mpz.GJB1 injected mice show improved myelination com-
pared with mock-treated littermates with fewer demyelinated (*) and
remyelinated (r) fibers in both tissues as well as fewer foamy macro-
phages (arrows in C). Quantification of the ratios of abnormally
myelinated fibers in multiple roots and femoral nerves (n= 10 mice
per group) confirms significant improvement in the numbers of
abnormally myelinated fibers (E) and (K) as well as significant
reduction in the numbers of foamy macrophages (F, L) in the treated
compared with mock treated littermates (see also Tables S4 and S6).
Scale bars: (A, B), (G, H) 50 μm, (C, D), (I, J) 10 μm.
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In this study, we demonstrate that targeted transduction
of Schwann cell of the peripheral nervous system can be
achieved after a single lumbar intrathecal injection using the
AAV9. AAV9 has been previously used mostly for CNS
transduction [60] but has not been studied specifically for
PNS targeting [61–63]. However, some studies showed that
AAV9 can transduce peripheral nerves after intrathecal
injection [64] with detection of EGFP expression in sciatic
nerves after intravenous or intrathecal injection in mice
[65, 66]. AAV9 has been mainly used in experimental
models of giant axonal neuropathy [61], spinal muscular
atrophy [67], and amyotrophic lateral sclerosis [68, 69].
These studies demonstrated that AAV9 can transduce effi-
ciently the CNS resulting in phenotype rescue of these
models. Furthermore, the AAV9 vector has been shown to
provide gene expression in non-human primates either by
intravenous [70] or by intrathecal [71] and recently by
subpial delivery [68]. However, there are limited data
concerning the efficacy of AAV9 to transduce the PNS. A
recent study showed a gradient of AAV9 biodistribution
into the PNS following lumbar intrathecal injection or
injection in the cisterna magna, with reporter gene expres-
sion also in the sciatic nerves [64]. In contrast to our study,
cell specificity of expression could not be demonstrated,
since ubiquitous promoters were used. The lower efficacy of
Schwann cell transduction after intrathecal injection in other
studies [64] could be in part attributed to the fourfold lower
volumes injected compared to our approach.
Improvement of functional properties in AAV9-Mpz.
GJB1 treated groups, including behavioral and electro-
physiological outcomes, indicate that treatment with this
vector not only results in expression of human Cx32 but also
in restoration of Cx32 function in myelinated fibers.
Although pre- and post-onset treatment groups were studied
at different time periods and may not be directly comparable,
almost similar improvements in functional properties were
observed at both time points, indicating that gene replace-
ment can be beneficial either before or after the onset of the
neuropathy, reversing some of the pathological changes that
are already present in older mice. Early treated mice showed
a trend for higher increase of hind limb force and more
improvement of MNCVs approaching those of age-matched
WT mice, while in post-onset treated mice they remained
significantly below those of WT mice. Thus, early inter-
vention may provide a bigger therapeutic benefit, although
not clearly demonstrated in all outcome measures, in
accordance with our previous studies [31, 33]. The relatively
slow progression of the pathological and functional changes
beyond 6 months of age in the Gjb1-null model at baseline
[25, 31, 33] may account for these observations.
By the time CMT1X patients become symptomatic,
typically by late childhood to young adulthood, they are
likely to have advanced pathological changes in their nerves
including demyelination and progressive axonal loss
[5, 23, 24, 72, 73]. Although the Gjb1-null mouse model
does not fully reproduce the degree of pathology in patients,
it develops a significant degree of demyelination and axonal
pathology especially in motor fibers at the ages of 6 to
10 months [25, 26, 30, 31, 52] in addition to inflammatory
changes with macrophage infiltration [53, 54]. Thus,
demonstration of post-onset efficacy of gene therapy in this
model indicates that viral expression and restoration of
Cx32 function can be effective even in an intraneural
environment of ongoing chronic de- and re-myelination,
axonal degeneration, and inflammation, and is therefore
highly relevant for the potential of clinical application.
The therapeutic benefit in this neuropathy model is further
demonstrated by the amelioration of NF-L plasma con-
centrations in AAV9-Mpz.GJB1 treated compared to the
mock-treated mice. NF-L is a biomarker that correlates with
peripheral nerve degeneration in patients with CMT1X and
other CMT types [51]. Since NF-L is associated with axonal
damage, we conclude that treatment with AAV9-Mpz.GJB1
either prevents or reverses axonal damage caused by the loss
of Cx32 in Schwann cells. Similar treatment responsiveness
of this biomarker was shown in our previous studies using
lentiviral gene therapy in CMT1X and CMT4C demyelinat-
ing neuropathy models [31, 74]. Interestingly, in this
study AAV9-treated Gjb1-null mice showed an even stronger
amelioration of NF-L levels approaching those of WT mice,
indicating that the therapeutic benefit and axonal protection
provided by AAV are stronger. These findings support the
use of the AAV9 vector for the treatment of demyelinating
neuropathies and confirm NF-L as a relevant biomarker
that can be used to measure treatment response in CMT1X
patients.
A further blood biomarker reflecting nerve pathology,
NCAM1, also showed significant treatment responsiveness.
Elevated NCAM1 serum levels have been previously asso-
ciated with various forms of inflammatory neuropathies and
with CMT1A [75] as well as with Alzheimer’s disease [76],
indicating that it may be a relatively broad marker of CNS
and PNS neurodegeneration. Furthermore, NCAM-1 was
shown to regulate synaptic reorganization after peripheral
nerve injury suggesting an important role during regenera-
tion [77]. We demonstrate here for the first time a significant
increase of NCAM-1 levels in 10-month-old Gjb1-null mice
compared to WT controls, highlighting its relevance for
CMT1X pathology. Importantly, treated Gjb1-null mice
showed a significant amelioration in serum NCAM-1 levels
compared to the mock group at 10 months of age, suggesting
the potential value of this biomarker in CMT1X. However,
further confirmatory studies in the serum of CMTX1 patients
are required to validate this finding.
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Our morphological analysis revealed that treatment with
the AAV9 vector results in improvement of the pathological
properties of all the PNS tissues examined. Both the ratios
of abnormally myelinated fibers and the numbers of foamy
macrophages were reduced in fully treated mice compared
to the mock group in both pre- and post-onset studies. The
percentage of improvement reached 60% for the roots and
the femoral nerve and 50% for the sciatic nerves, although
baseline values were higher in late treated mice as expected
based on the pathology progression in the Gjb1-null mouse
model [30]. Stronger improvement in tissues with motor
fibers including the anterior lumbar roots and femoral motor
branches likely reflects the fact that neuropathy in this
model affects predominantly the motor fibers [25, 78].
Overall, our data indicate that AAV9-mediated delivery of
Cx32 can improve PNS pathology both before and after the
onset of the CMT1X neuropathy.
In conclusion, this study provides the proof of principle
that intrathecal injection of AAV9, a well-established vector
for clinical applications, provides widespread biodistribu-
tion in the PNS and efficient transduction of myelinating
Schwann cells. Moreover, Schwann cell-targeted expression
of Cx32 driven by a myelin-specific promoter can prevent
or even reverse the demyelination and axonal degeneration
occurring in the CMT1X mouse model providing a long-
lasting therapeutic benefit even after the onset of the neu-
ropathy. Evaluation of this approach in larger animal
models would be valuable in order to confirm adequate
biodistribution and safety facilitating the path towards
clinical translation for treating CMT1X patients.
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